These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33214397)

  • 21. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
    Hoy SM
    CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implementing a Global Expanded Access Program (EAP) for Infantile-Onset Spinal Muscular Atrophy (Type I): Understanding the Imperative, Impact and Challenges.
    Yong J; Moffett M; Lucas S
    J Neuromuscul Dis; 2019; 6(2):227-231. PubMed ID: 31127730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changing respiratory expectations with the new disease trajectory of nusinersen treated spinal muscular atrophy [SMA] type 1.
    Fitzgerald DA; Doumit M; Abel F
    Paediatr Respir Rev; 2018 Sep; 28():11-17. PubMed ID: 30414815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Outcomes in Patients with Spinal Muscular Atrophy Type 1 Treated with Nusinersen.
    de Holanda Mendonça R; Jorge Polido G; Ciro M; Jorge Fontoura Solla D; Conti Reed U; Zanoteli E
    J Neuromuscul Dis; 2021; 8(2):217-224. PubMed ID: 33459657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in electrophysiological findings of spinal muscular atrophy type I after the administration of nusinersen and onasemnogene abeparvovec: two case reports.
    Mizuno T; Kanouchi T; Tamura Y; Hirata K; Emoto R; Suzuki T; Kashimada K; Morio T
    BMC Neurol; 2023 Oct; 23(1):392. PubMed ID: 37907848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inflammatory markers in cerebrospinal fluid of paediatric spinal muscular atrophy patients receiving nusinersen treatment.
    Scheijmans FEV; Cuppen I; Zwartkruis MM; Signoria I; van Ekris C; Asselman F; Wadman RI; Knol EF; van der Pol WL; Groen EJN
    Eur J Paediatr Neurol; 2023 Jan; 42():34-41. PubMed ID: 36525882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nutritional Therapy in Children With Spinal Muscular Atrophy in the Era of Nusinersen.
    Yerushalmy-Feler A; Levy D; Sagi L; Fattal-Valevski A; Shiff YE; Brener A; Cohen S
    J Pediatr Gastroenterol Nutr; 2021 Jun; 72(6):e154-e160. PubMed ID: 33492038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies.
    Darras BT; Chiriboga CA; Iannaccone ST; Swoboda KJ; Montes J; Mignon L; Xia S; Bennett CF; Bishop KM; Shefner JM; Green AM; Sun P; Bhan I; Gheuens S; Schneider E; Farwell W; De Vivo DC;
    Neurology; 2019 May; 92(21):e2492-e2506. PubMed ID: 31019106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland.
    Tscherter A; Rüsch CT; Baumann D; Enzmann C; Hasselmann O; Jacquier D; Jung HH; Kruijshaar ME; Kuehni CE; Neuwirth C; Stettner GM; Klein A;
    Neuromuscul Disord; 2022 May; 32(5):399-409. PubMed ID: 35337708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
    Mercuri E; Darras BT; Chiriboga CA; Day JW; Campbell C; Connolly AM; Iannaccone ST; Kirschner J; Kuntz NL; Saito K; Shieh PB; Tulinius M; Mazzone ES; Montes J; Bishop KM; Yang Q; Foster R; Gheuens S; Bennett CF; Farwell W; Schneider E; De Vivo DC; Finkel RS;
    N Engl J Med; 2018 Feb; 378(7):625-635. PubMed ID: 29443664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nusinersen for spinal muscular atrophy type 1: Real-world respiratory experience.
    Lavie M; Diamant N; Cahal M; Sadot E; Be'er M; Fattal-Valevski A; Sagi L; Domany KA; Amirav I
    Pediatr Pulmonol; 2021 Jan; 56(1):291-298. PubMed ID: 33111497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlations between clinical motor scores and CMAP in patients with type 2 spinal muscular amyotrophy treated with nusinersen.
    Richard M; Barrois R; Desguerre I; Deladrière E; Leloup-Germa V; Barnerias C; Gitiaux C
    Arch Pediatr; 2024 Jan; 31(1):26-31. PubMed ID: 37989659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nusinersen improved respiratory function in spinal muscular atrophy type 2.
    Tanaka R; Fukushima F; Motoyama K; Kobayashi C; Izumi I
    Pediatr Int; 2021 Aug; 63(8):973-974. PubMed ID: 34245199
    [No Abstract]   [Full Text] [Related]  

  • 34. Impaired diaphragmatic motility in treatment-naive adult patients with spinal muscular atrophy improved during nusinersen treatment.
    Freigang M; Langner S; Hermann A; Günther R
    Muscle Nerve; 2023 Sep; 68(3):278-285. PubMed ID: 37466180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
    Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
    Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study.
    Acsadi G; Crawford TO; Müller-Felber W; Shieh PB; Richardson R; Natarajan N; Castro D; Ramirez-Schrempp D; Gambino G; Sun P; Farwell W
    Muscle Nerve; 2021 May; 63(5):668-677. PubMed ID: 33501671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
    Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
    J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
    [No Abstract]   [Full Text] [Related]  

  • 39. Maximum bite force in patients with spinal muscular atrophy during the first year of nusinersen therapy - A pilot study.
    Kruse T; Heller R; Wirth B; Glöggler J; Wurster CD; Ludolph AC; Braumann B
    Acta Myol; 2020 Jun; 39(2):83-89. PubMed ID: 32904902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful Combination of Neuraxial and Regional Anesthesia in a Child With Advanced Spinal Muscular Atrophy Type 1 Receiving Maintenance Nusinersen Therapy: A Case Report.
    Brown AF; Einhorn LM
    A A Pract; 2020 Apr; 14(6):e01206. PubMed ID: 32784322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.